Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook

TipRanksMay 10 01:41 ET

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.

BenzingaMay 9 06:53 ET

Karyopharm Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 684.31% HC Wainwright & Co. → $8 Reiterates Buy → Buy 03/01/2024 684.31% HC Wainwright & Co. $1

BenzingaMay 9 06:52 ET

Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials

TipRanksMay 9 06:27 ET

Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays

TipRanksMay 9 03:26 ET

Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Yahoo FinanceMay 9 03:02 ET